
import { Question, Answers } from '../types';

export const getQuestions = (tab: string): Question[] => {
  const questionSets: { [key: string]: Question[] } = {
    'stage1': [
      {
        key: 'operability',
        question: 'Le patient est-il opÃ©rable selon l\'Ã©valuation multidisciplinaire ?',
        options: [
          { value: 'operable', label: 'âœ… OpÃ©rable (bon Ã©tat gÃ©nÃ©ral, fonction respiratoire suffisante, absence de comorbiditÃ©s majeures)' },
          { value: 'inoperable', label: 'âŒ InopÃ©rable (comorbiditÃ©s, fonction respiratoire insuffisante, refus patient)' }
        ]
      },
      {
        key: 'surgery_result',
        question: 'Quel est le rÃ©sultat anatomopathologique de la chirurgie ?',
        condition: (answers: Answers) => answers.operability === 'operable',
        options: [
          { value: 'complete_pIA', label: 'ğŸŸ¢ ExÃ©rÃ¨se complÃ¨te R0 - pTis, pT1a-c N0 (Stade pIA)' },
          { value: 'complete_pIB', label: 'ğŸŸ¡ ExÃ©rÃ¨se complÃ¨te R0 - pT2a N0 (Stade pIB)' },
          { value: 'incomplete_R1', label: 'ğŸŸ  ExÃ©rÃ¨se incomplÃ¨te R1 (rÃ©sidu microscopique)' },
          { value: 'incomplete_R2', label: 'ğŸ”´ ExÃ©rÃ¨se incomplÃ¨te R2 (rÃ©sidu macroscopique)' },
          { value: 'node_discovery', label: 'âš ï¸ DÃ©couverte ganglions pN1/N2 post-opÃ©ratoire' }
        ]
      },
      {
        key: 'egfr_mutation',
        question: 'Y a-t-il une mutation EGFR sensibilisante (Del19, L858R) ?',
        condition: (answers: Answers) => answers.surgery_result === 'complete_pIB',
        options: [
          { value: 'yes', label: 'âœ… Oui - Mutation EGFR Del19 ou L858R confirmÃ©e' },
          { value: 'no', label: 'âŒ Non / Statut inconnu / Autre mutation EGFR' }
        ]
      }
    ],
    
    'stage2-3': [
      {
        key: 'resectability',
        question: 'Quelle est l\'Ã©valuation de rÃ©sÃ©cabilitÃ© aprÃ¨s bilan multidisciplinaire ?',
        options: [
          { value: 'resectable', label: 'ğŸŸ¢ RÃ©sÃ©cable et opÃ©rable (T1-3, N0-1 rÃ©sÃ©cables)' },
          { value: 'unresectable_stage2', label: 'ğŸŸ¡ Non opÃ©rable - Stade II (comorbiditÃ©s, fonction respiratoire)' },
          { value: 'unresectable_stage3', label: 'ğŸ”´ Non Ã©ligible Ã  la chirurgie - Stade III (N2-3, T4)' }
        ]
      },
      {
        key: 'molecular_profile',
        question: 'Quel est le profil molÃ©culaire tumoral ?',
        condition: (answers: Answers) => answers.resectability === 'resectable',
        options: [
          { value: 'pdl1_low', label: 'ğŸ”µ PDL1 <1% + EGFR/ALK sauvages' },
          { value: 'pdl1_high', label: 'ğŸŸ¢ PDL1 â‰¥ 1% + EGFR/ALK sauvages' },
          { value: 'egfr_mutated', label: 'ğŸ§¬ Mutation EGFR Del19/L858R' },
          { value: 'alk_rearranged', label: 'ğŸ§¬ RÃ©arrangement ALK' }
        ]
      }
    ],

    'stage3advanced': [
      {
        key: 'performance_status',
        question: 'Quel est le performance status (PS) et l\'Ã¢ge du patient ?',
        options: [
          { value: 'ps0_1_young', label: 'ğŸŸ¢ PS 0-1 et Ã¢ge â‰¤ 70 ans (option jusqu\'Ã  75 ans)' },
          { value: 'ps2_old', label: 'ğŸŸ¡ PS 2 ou Ã¢ge > 70 ans' }
        ]
      },
      {
        key: 'treatment_response',
        question: 'Quelle est l\'Ã©volution aprÃ¨s radio-chimiothÃ©rapie ?',
        condition: (answers: Answers) => !!answers.performance_status, // Check if previous question was answered
        options: [
          { value: 'non_progressive', label: 'âœ… Non progressif et PS â‰¤ 1 (Ã©ligible maintenance)' },
          { value: 'progressive', label: 'ğŸ“ˆ Progression de maladie (discussion en RCP)' }
        ]
      },
      {
        key: 'molecular_status',
        question: 'Quel est le statut molÃ©culaire pour la maintenance ?',
        condition: (answers: Answers) => answers.treatment_response === 'non_progressive',
        options: [
          { value: 'egfr_alk_wt', label: 'ğŸ”µ EGFR et ALK sauvages (ou PDL1<1% et inconnus pour Durvalumab)' },
          { value: 'egfr_mutated', label: 'ğŸ§¬ Mutation EGFR Del19/L858R' }
        ]
      }
    ],

    'apex': [
      {
        key: 'nodal_status',
        question: 'Quel est le statut ganglionnaire de la tumeur de Pancoast (Apex) ?',
        options: [
          { value: 'cN0_1', label: 'ğŸŸ¢ cN0-1 (pas d\'envahissement ganglionnaire majeur)' },
          { value: 'cN2_3', label: 'ğŸ”´ cN2-3 (envahissement ganglionnaire mÃ©diastinal)' }
        ]
      },
      {
        key: 'resectability_post_rt',
        question: 'AprÃ¨s radio-chimiothÃ©rapie d\'induction (46Gy), la tumeur est-elle rÃ©sÃ©cable ?',
        condition: (answers: Answers) => answers.nodal_status === 'cN0_1',
        options: [
          { value: 'resectable', label: 'âœ… Oui, rÃ©sÃ©cable' },
          { value: 'unresectable', label: 'âŒ Non, non rÃ©sÃ©cable' }
        ]
      }
    ],

    'stage4-nonepi': [
      {
        key: 'pdl1_status',
        question: 'Quel est le taux d\'expression PD-L1 (TPS) ?',
        options: [
          { value: 'high', label: 'ğŸŸ¢ PD-L1 â‰¥ 50% (forte expression)' },
          { value: 'low', label: 'ğŸ”µ PD-L1 < 50% (faible expression)' }
        ]
      },
      {
        key: 'performance_status',
        question: 'Quel est le performance status (PS) et l\'Ã¢ge du patient ?',
        options: [
          { value: 'ps0_1', label: 'ğŸŸ¢ PS 0-1' },
          { value: 'ps2_age_ge70', label: 'ğŸŸ¡ PS 2 ou Ã‚ge â‰¥ 70 ans' },
          { value: 'ps_gt2', label: 'ğŸ”´ PS > 2' }
        ]
      }
    ],

    'stage4-epi': [
       {
        key: 'pdl1_status',
        question: 'Quel est le taux d\'expression PD-L1 (TPS) ?',
        options: [
          { value: 'high', label: 'ğŸŸ¢ PD-L1 â‰¥ 50% (forte expression)' },
          { value: 'low', label: 'ğŸ”µ PD-L1 < 50% (faible expression)' }
        ]
      },
      {
        key: 'performance_status',
        question: 'Quel est le performance status (PS) et l\'Ã¢ge du patient ?',
        options: [
          { value: 'ps0_1', label: 'ğŸŸ¢ PS 0-1' },
          { value: 'ps2_age_ge70', label: 'ğŸŸ¡ PS 2 ou Ã‚ge â‰¥ 70 ans' },
          { value: 'ps_gt2', label: 'ğŸ”´ PS > 2' }
        ]
      }
    ],

    'stage4-second': [
      {
        key: 'performance_status',
        question: 'Quel est le performance status actuel du patient (PS) ?',
        options: [
          { value: 'ps0_2', label: 'ğŸŸ¢ PS 0-2 (Ã©ligible Ã  un traitement)' },
          { value: 'ps_gt2', label: 'ğŸ”´ PS > 2 (soins de support)' }
        ]
      },
      {
        key: 'first_line_treatment_type',
        question: 'Quel Ã©tait le type de traitement de premiÃ¨re ligne ?',
        condition: (answers: Answers) => answers.performance_status === 'ps0_2',
        options: [
          { value: 'chemo_immuno', label: 'ğŸ’Š+ğŸ›¡ï¸ ChimiothÃ©rapie + ImmunothÃ©rapie' },
          { value: 'immuno_alone', label: 'ğŸ›¡ï¸ ImmunothÃ©rapie seule' },
          { value: 'chemo_alone', label: 'ğŸ’Š ChimiothÃ©rapie seule' }
        ]
      },
      {
        key: 'histology',
        question: 'Quelle est l\'histologie tumorale ? (Si 1Ã¨re ligne = ChimiothÃ©rapie seule OU ImmunothÃ©rapie seule)',
        condition: (answers: Answers) => (answers.performance_status === 'ps0_2' && (answers.first_line_treatment_type === 'chemo_alone' || answers.first_line_treatment_type === 'immuno_alone')),
        options: [
          { value: 'non_epidermoid', label: 'ğŸ”µ Non-Ã©pidermoÃ¯de (adÃ©nocarcinome, grandes cellules)' },
          { value: 'epidermoid', label: 'ğŸŸ¤ Ã‰pidermoÃ¯de' }
        ]
      },
      {
        key: 'pdl1_status_second_line',
        question: 'PDL1 â‰¥ 1% ? (Si 1Ã¨re ligne = ChimiothÃ©rapie seule)',
        condition: (answers: Answers) => answers.performance_status === 'ps0_2' && answers.first_line_treatment_type === 'chemo_alone',
        options: [
          { value: 'yes', label: 'âœ… Oui, PDL1 â‰¥ 1%' },
          { value: 'no', label: 'âŒ Non, PDL1 < 1%' }
        ]
      },
       {
        key: 'cmet_ihc',
        question: 'Statut cMET surexprimÃ© (IHC) ?',
        condition: (answers: Answers) => answers.performance_status === 'ps0_2',
        options: [
          { value: 'positive', label: 'âœ… Positif' },
          { value: 'negative_unknown', label: 'âŒ NÃ©gatif ou Inconnu' }
        ]
      }
    ],

    'egfr': [
      {
        key: 'mutation_type',
        question: 'Quel type de mutation EGFR a Ã©tÃ© identifiÃ©e ?',
        options: [
          { value: 'del19_l858r', label: 'ğŸŸ¢ Del19 ou L858R (mutations sensibilisantes classiques)' },
          { value: 't790m', label: 'ğŸ”´ T790M (mutation de rÃ©sistance)' },
          { value: 'other_sensitizing', label: 'ğŸŸ¡ G719X, L861Q, S768I, mutations combinÃ©es (multiples)' },
          { value: 'exon20_insertion', label: 'ğŸ”´ Insertion dans l\'exon 20' }
        ]
      },
      {
        key: 'treatment_context',
        question: 'Dans quel contexte thÃ©rapeutique (pour Del19/L858R ou T790M) ?',
        condition: (answers: Answers) => answers.mutation_type === 'del19_l858r' || answers.mutation_type === 't790m',
        options: [
          { value: 'first_line', label: '1ï¸âƒ£ PremiÃ¨re ligne mÃ©tastatique' },
          { value: 'progression_on_tki', label: 'ğŸ“ˆ Progression sous ITK EGFR (Osimertinib ou autre)' }
        ]
      },
      {
        key: 'progression_type_egfr',
        question: 'Quel type de progression sous ITK EGFR ?',
        condition: (answers: Answers) => (answers.mutation_type === 'del19_l858r' || answers.mutation_type === 'other_sensitizing') && answers.treatment_context === 'progression_on_tki',
        options: [
          { value: 'oligometastatic', label: 'ğŸ¯ OligomÃ©tastatique (â‰¤3 sites, discussion traitement local)' },
          { value: 'slow', label: 'ğŸŒ Lente (discussion poursuite ITK si bÃ©nÃ©fice)' },
          { value: 'multifocal', label: 'âš¡ Multifocale/franche (re-biopsie, adaptation traitement)' }
        ]
      }
    ],

    'alk': [
      {
        key: 'treatment_phase',
        question: 'Phase de traitement pour rÃ©arrangement ALK ?',
        options: [
          { value: 'first_line', label: '1ï¸âƒ£ PremiÃ¨re ligne mÃ©tastatique' },
          { value: 'resistance_progression', label: 'ğŸ“ˆ RÃ©sistance/Progression sous ITK ALK' }
        ]
      },
      {
        key: 'resistance_type_alk',
        question: 'Type de rÃ©sistance/progression ?',
        condition: (answers: Answers) => answers.treatment_phase === 'resistance_progression',
        options: [
          { value: 'primary_resistance', label: 'âš¡ RÃ©sistance primaire (vÃ©rifier observance, interactions)' },
          { value: 'acquired_resistance', label: 'ğŸ“ˆ RÃ©sistance acquise (aprÃ¨s rÃ©ponse initiale)' }
        ]
      },
      {
        key: 'previous_tki_alk',
        question: 'Quel ITK ALK Ã©tait utilisÃ© avant la progression (si rÃ©sistance acquise) ?',
        condition: (answers: Answers) => answers.resistance_type_alk === 'acquired_resistance',
        options: [
          { value: 'alectinib_brigatinib', label: 'ğŸ’Š Alectinib ou Brigatinib' },
          { value: 'lorlatinib', label: 'ğŸ’Š Lorlatinib' },
          { value: 'other_tki', label: 'ğŸ’Š Autre ITK ALK de 1Ã¨re/2Ã¨me gÃ©nÃ©ration' }
        ]
      },
      {
        key: 'progression_pattern_alk',
        question: 'Quel est le mode de progression (si rÃ©sistance acquise) ?',
        condition: (answers: Answers) => answers.resistance_type_alk === 'acquired_resistance',
        options: [
          { value: 'oligometastatic', label: 'ğŸ¯ OligomÃ©tastatique (traitement local + poursuite ITK)' },
          { value: 'slow', label: 'ğŸŒ Ã‰volution lente (poursuite ITK si bÃ©nÃ©fice clinique)' },
          { value: 'multifocal', label: 'âš¡ Ã‰volution multifocale (Rebiopsie / ADN circulant si disponible)' }
        ]
      }
    ],

    'other-mutations': [
      {
        key: 'mutation_type',
        question: 'Quelle altÃ©ration molÃ©culaire rare a Ã©tÃ© identifiÃ©e ?',
        options: [
          { value: 'ros1', label: 'ğŸ§¬ RÃ©arrangement ROS1' },
          { value: 'ret', label: 'ğŸ§¬ RÃ©arrangement RET' },
          { value: 'ntrk', label: 'ğŸ§¬ Fusion NTRK1/2/3' },
          { value: 'kras_g12c', label: 'ğŸ§¬ Mutation KRAS G12C' },
          { value: 'met_exon14', label: 'ğŸ§¬ Saut d\'exon 14 de MET (METex14)' },
          { value: 'her2', label: 'ğŸ§¬ Mutation HER2 (ERBB2)' }
          // BRAF V600E non listÃ© dans les arbres decisionnels principaux, mais pourrait Ãªtre ajoutÃ©.
        ]
      }
    ]
  };
  
  return questionSets[tab] || [];
};
